| Market Cap | 8.54B |
| Revenue (ttm) | 38.02B |
| Net Income (ttm) | 598.54M |
| Shares Out | n/a |
| EPS (ttm) | 0.16 |
| PE Ratio | 14.27 |
| Forward PE | 13.02 |
| Dividend | 0.24 (3.43%) |
| Ex-Dividend Date | Sep 19, 2024 |
| Volume | 395 |
| Average Volume | 11 |
| Open | 7.00 |
| Previous Close | 6.83 |
| Day's Range | 6.83 - 7.09 |
| 52-Week Range | 5.96 - 9.44 |
| Beta | 0.45 |
| RSI | 28.58 |
| Earnings Date | Aug 26, 2025 |
About SHPMY
Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, syste... [Read more]
Financial Performance
In 2024, SHPMY's revenue was 275.25 billion, an increase of 5.75% compared to the previous year's 260.30 billion. Earnings were 4.55 billion, an increase of 20.82%.
Financial numbers in CNY Financial StatementsNews
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million ...